Effect of Bcl-2 expression on hepatic preneoplasia in mice

Cancer Letters

Volumn 177, Issue 2, 2002, Pages 189-195

  Gillet, Raphaëlle ^a   Grimber, Gisèle ^a   Cavard, Catherine ^a   Bennoun, Myriam ^a   Mignon, Alexandre ^b   Briand, Pascale ^a   Joulin, Virginie ^a  

^a INSTITUT COCHIN   (France)

^b INSERM   (France)

Author keywords

Apoptosis; Bcl 2; Hepatocellular carcinoma; Preneoplasia; SV40 large T antigen; Transgenic

Indexed keywords

PROTEIN BCL 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; HEPATOMEGALY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSGENIC MOUSE;

MUS MUSCULUS;

EID: 0037187471     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(01)00789-3     Document Type: Article

References (33)

1. The hallmarks of cancer
2. Compensatory apoptosis in response to SV40 large T antigen expression in the liver
3. Inherent increase of apoptosis in liver tumors: Implications for carcinogenesis and tumor regression
4. Compensatory apoptosis in preneoplastic liver of a transgenic mouse model for viral hepatocarcinogenesis
5. Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha
6. Quantitative analysis of changes in cell proliferation and apoptosis during preneoplastic and neoplastic stages of hepatocarcinogenesis in rat
7. Time-course development of differentiated hepatocarcinoma and lung metastasis in transgenic mice
8. Involvement of the bcl-2 gene in human follicular lymphoma
9. Bcl-2 overexpression blocks activation of the death protease CPP32/Yama/apopain
10. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death
11. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked
12. A link between cell cycle and cell death: Bax and Bcl-2 modulate Cdk2 activation during thymocyte apoptosis
13. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry
14. Expression of apoptosis, proliferating cell nuclear antigen, and apoptosis-related antigens (bcl-2, c-myc, Fas, Lewis(y) and p53) in human cholangiocarcinomas and hepatocellular carcinomas
15. Inverse correlation between bcl-2 expression and cell growth fraction in human endometrial adenocarcinoma tissue
16. High levels of BCL-2 messenger RNA detected by in situ hybridization in human hepatocellular and cholangiocellular carcinomas
17. Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice
18. The consequence of p53 overexpression for liver development and the response of transformed murine hepatocytes to genotoxic stress
19. Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice
20. Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: Reduction in protective apoptotic response at the preneoplastic stage
21. Diminished cell proliferation associated with the death-protective activity of Bcl-2
22. Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation
23. Regulation of cell division cycle progression by bcl-2 expression: A potential mechanism for inhibition of programmed cell death
24. Bcl-2-induced changes in E2F regulatory complexes reveal the potential for integrated cell cycle and cell death functions
25. Bcl-2 retards cell cycle entry through p27(Kip1), pRB relative p130, and altered E2F regulation
26. The J domain of simian virus 40 large T antigen is required to functionally inactivate RB family proteins
27. Loss of anti-mitotic effects of Bcl-2 with retention of anti-apoptotic activity during tumor progression in a mouse model
28. WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis
29. Bcl-2 expression delays mammary tumor development in dimethylbenz(a)anthracene-treated transgenic mice
30. Bcl-2 accelerates multistep prostate carcinogenesis in vivo
31. Paradoxical inhibition of c-myc-induced carcinogenesis by Bcl-2 in transgenic mice
32. Bcl-2 delays and alters hepatic carcinogenesis induced by transforming growth factor α
33. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry